Effect of FOLFOX neoadjuvant chemotherapy on P53 protein and VEGF expression on gastric cancer

Abstract

Objective To study the effect of FOLFOX neoadjuvant chemotherapy on P53 protein and vascular endothelial growth factor（VEGF）expression in patients with gastric cancer. Methods Eighty-six patients with gastric cancer were enrolled as study object. The 43 cases in control group were treated with surgery only and 43 cases in the observation group were given FOLFOX neoadjuvant chemo-therapy before surgery. The surgical results were evaluated. P53 protein and VEGF expression in gastric carcinoma were detected by immunohistochemistry before and after chemotherapy. Results In the obser-vation group,the R0 resection rate and D2 lymph node dissection rate was significantly higher than that in the control group（P ﹤ 0. 05）. In the observation group,the average diameter of the tumor after chemo-therapy was significantly reduced,there was significant difference before and after treatment（P ﹤ 0. 05）. The total effective rate of chemotherapy was 53. 5% . The adverse reactions mainly were neutropenia, nausea and sensory nerve toxicity, most reactions were mild. Before chemotherapy,the P53 positive rate was 58. 1% ,the VEGF positive rate was 76. 7% in gastric carcinoma tissue of the ob-servation group;after chemotherapy,the P53 positive rate was 32. 6% ,the VEGF positive rate was 30. 2% of the observation group. The P53 and VEGF positive rate was significantly lower after chemo-therapy（P ﹤ 0. 01）. Conclusions FOLFOX neoadjuvant chemotherapy can obviously decrease P53 pro-tein and VEGF expression in gastric carcinoma tissue,so as to improve the surgery effect. Key words: Gastric cancer; Chemotherapy; P53 protein; Vascular endothelial growth factor